T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results ...

Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

The Mike Slive Foundation has named the recipients of six prostate cancer research grants. The grants are aimed at continuing the foundation’s stated mission ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Kazia Therapeutics is at the forefront of developing cutting-edge cancer therapies, with a key focus on brain cancer and aggressive tumor types like triple-negative breast cancer. The company’s ...